Related Experiment Video
Updated: Mar 5, 2026
A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided
Sergio García-Blas1, Clara Bonanad1, Pau Llàcer2
1Servicio de Cardiología, Hospital Clínico Universitario de Valencia, Universidad de Valencia, INCLIVA, Valencia, Spain.
Insights
This study investigates using carbohydrate antigen 125 (CA125) to guide diuretic therapy for acute heart failure with cardiorenal syndrome type 1. Higher CA125 levels may indicate benefit from intense diuretic treatment in CRS-1 patients.
Area of Science:
- Cardiology
- Nephrology
- Biomarkers
Background:
- Acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) management is challenging.
- Arterial hypoperfusion and venous congestion are key in CRS-1 pathophysiology.
- Plasma carbohydrate antigen 125 (CA125) indicates fluid overload in AHF.
Purpose of the Study:
- To assess the clinical utility of CA125 in optimizing diuretic therapy for CRS-1 patients.
- To determine if CA125 levels can guide diuretic intensity in AHF with CRS-1.
- To improve treatment strategies for AHF patients with cardiorenal complications.
Main Methods:
- Multicenter, open-label, randomized clinical trial.
- Patients with AHF and elevated creatinine randomized to standard or CA125-guided diuretic strategies.
- Primary endpoint: renal function changes at 24 and 72 hours.
Main Results:
- Study results will elucidate CA125's role in diuretic management for CRS-1.
- Findings will contribute to understanding CRS-1 pathophysiology.
- Data will inform personalized treatment approaches for AHF patients.
Conclusions:
- Higher CA125 levels may identify CRS-1 patients benefiting from intensified diuretic therapy.
- Lower CA125 levels might suggest that high diuretic doses could be detrimental.
- CA125 has potential as a biomarker for tailoring diuretic treatment in CRS-1.
Introduction And Objectives:
The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1.
Methods:
Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4mg/dL on admission will be randomized to: a) standard diuretic strategy: titration-based on conventional clinical and biochemical evaluation, or b) diuretic strategy based on CA125: high dose if CA125 > 35 U/mL, and low doses otherwise. The main endpoint will be renal function changes at 24 and 72hours after therapy initiation. Secondary endpoints will include: a) clinical and biochemical changes at 24 and 72hours, and b) renal function changes and major clinical events at 30 days.
Results:
The results of this study will add important knowledge on the usefulness of CA125 for guiding diuretic treatment in CRS-1. In addition, it will pave the way toward a better knowledge of the pathophysiology of this challenging situation.
Conclusions:
We hypothesize that higher levels of CA125 will identify a patient population with CRS-1 who could benefit from the use of a more intense diuretic strategy. Conversely, low levels of this glycoprotein could select those patients who would be harmed by high diuretic doses.
Related Concept Videos
01:22Heart Failure Drugs: Diuretics
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Acute Kidney Injury VI: Nursing Management
01:20Acute Kidney Injury V: Interprofessional Care